Edition:
United States

Radius Health Inc (RDUS.OQ)

RDUS.OQ on NASDAQ Stock Exchange Global Market

38.20USD
10:56am EST
Change (% chg)

$0.29 (+0.76%)
Prev Close
$37.91
Open
$37.49
Day's High
$38.40
Day's Low
$37.01
Volume
71,510
Avg. Vol
308,998
52-wk High
$49.15
52-wk Low
$24.68

Latest Key Developments (Source: Significant Developments)

Radius Health Expects CHMP To Issue Opinion Regarding Marketing Authorization Application Of Abaloparatide-Sc during H1 2018
Friday, 15 Dec 2017 07:31am EST 

Dec 15 (Reuters) - Radius Health Inc ::RADIUS HEALTH ANNOUNCES THAT THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) WILL ISSUE A THIRD DAY-180 LIST OF OUTSTANDING ISSUES IN ITS REGULATORY REVIEW OF ABALOPARATIDE-SC, A BONE BUILDING AGENT FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURE.RADIUS HEALTH-EXPECTS COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE TO ISSUE AN OPINION REGARDING MARKETING AUTHORISATION APPLICATION DURING H1 2018.  Full Article

Radius Health reports Q3 loss per share $1.31
Thursday, 2 Nov 2017 04:01pm EDT 

Nov 2 (Reuters) - Radius Health Inc :Radius Health Inc reports third quarter 2017 financial and operating results and provides business update.Q3 loss per share $1.31.Q3 earnings per share view $-1.26 -- Thomson Reuters I/B/E/S.Radius Health Inc - ‍expects to submit a labeling supplement to FDA in connection with activextend results by end of 2017​.Radius health inc - ‍expects to reduce size of board from 10 to 9 members​.Radius Health Inc - believe have sufficient capital to fund development plans, U.S. Commercial and other operational activities for not less than 12 months​.  Full Article

Radius Health receives FDA fast track designation for elacestrant
Wednesday, 18 Oct 2017 09:00am EDT 

Oct 18 (Reuters) - Radius Health Inc :Radius health receives fda fast track designation for elacestrant (rad1901).Radius health - ‍plans to initiate phase 2 clinical study of elacestrant as a third-line therapy for women with er+ and her2- breast cancer early in 2018​.Radius health inc - ‍expect to enroll first patient in phase 2 study in early 2018​.  Full Article

Radius Health initiates Phase 1 clinical trial of RAD140 for treatment of hormone receptor positive breast cancer
Friday, 29 Sep 2017 08:45am EDT 

Sept 29 (Reuters) - Radius Health Inc :Radius Health initiates Phase 1 clinical trial of RAD140 for the treatment of hormone receptor positive breast cancer.Radius Health Inc - ‍clinical trial is designed to evaluate safety and maximum tolerated dose of RAD140 in approximately 40 patients​.Radius Health Inc - pharmacokinetics, pharmacodynamics and tumor response will also be evaluated in Phase 1 trial​.  Full Article

Radius Health prices $300 mln of 3 pct convertible senior notes due 2024
Tuesday, 8 Aug 2017 11:16pm EDT 

Aug 8 (Reuters) - Radius Health Inc :Radius Health announces pricing of $300 million of 3.00 percent convertible senior notes due 2024.Notes will pay interest semi-annually in arrears on March 1 and September 1 of each year at rate of 3.00 percent per year.Estimates that net proceeds from offering of notes will be approximately $290.8 million.  Full Article

Radius Health announces proposed public offering of $300 million of convertible senior notes due 2024
Monday, 7 Aug 2017 04:22pm EDT 

Aug 7 (Reuters) - Radius Health Inc :Radius Health - to use net proceeds to support U.S. commercial launch of Tymlos injection, development of its life cycle management activities​.  Full Article

Radius Health reports Q2 loss per share $1.58
Thursday, 3 Aug 2017 04:01pm EDT 

Aug 3 (Reuters) - Radius Health Inc :Radius Health reports second quarter 2017 financial and operating results and provides business update.Q2 loss per share $1.58.Q2 earnings per share view $-1.23 -- Thomson Reuters I/B/E/S.  Full Article

Radius Health says CHMP has issued second day-180 list of outstanding issues in its regulatory review of Eladynos
Friday, 21 Jul 2017 04:05pm EDT 

July 21 (Reuters) - Radius Health Inc ::Radius health announces that the committee for medicinal products for human use (chmp) has issued a second day-180 list of outstanding issues in its regulatory review of Eladynos™ (abaloparatide-sc), a bone building agent for the treatment of postmenopausal women with osteoporosis at high risk for fracture.Radius Health Inc - radius expects chmp to issue an opinion regarding maa for abaloparatide-sc prior to end of 2017..Radius health inc - if approved, abaloparatide-sc to be marketed in European union as eladynos.  Full Article

Radius Health appoints Jesper Høiland as president and CEO
Monday, 17 Jul 2017 07:00am EDT 

July 17 (Reuters) - Radius Health Inc :Radius Health appoints Jesper Høiland as president and chief executive officer to lead the next stage of growth and value creation as a fully integrated commercial biotech company.Radius Health Inc - ‍prior to joining Radius, Høiland served as president of Novo Nordisk Inc USA​.  Full Article

Radius Health announces license and development agreement for Abaloparatide-Sc with Teijin Limited in Japan
Thursday, 13 Jul 2017 07:40am EDT 

July 13 (Reuters) - Radius Health Inc ;:Radius Health announces license and development agreement for Abaloparatide-Sc with Teijin Limited in Japan.Radius Health Inc - ‍radius to receive upfront and milestone payments, royalties, and an option for co-promotion​.Radius Health - ‍Teijin granted a right of reference to Radius regulatory data.Radius Health - co maintains full global rights to its development program for Abaloparatide-Transdermal which is not part of agreement with Teijin.Radius Health - ‍Teijin also granted use of Radius intellectual property for development, manufacture and commercialization of abaloparatide-sc for Japan​.Radius Health Inc - ‍collaboration agreement provides Teijin with right to manufacture abaloparatide-sc for commercial supply in Japan​.Radius Health-‍Teijin conducting, funding Japanese phase 3 development program; parties may further collaborate in future in new indications for product​.  Full Article

BRIEF-Radius Health Expects CHMP To Issue Opinion Regarding Marketing Authorization Application Of Abaloparatide-Sc during H1 2018

* RADIUS HEALTH ANNOUNCES THAT THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) WILL ISSUE A THIRD DAY-180 LIST OF OUTSTANDING ISSUES IN ITS REGULATORY REVIEW OF ABALOPARATIDE-SC, A BONE BUILDING AGENT FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURE